

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2018/12/31	2017/12/31
Balance Sheet		
Current assets		
Cash and cash equivalents	215,745	342,061
Current financial assets at amortised cost	88,599	0
Current contract assets	5,501	0
Current investments in debt instrument without active market	0	283,586
Accounts receivable, net	50,535	67,304
Accounts receivable due from related parties, net	293	1,533
Other receivables	9,771	1,262
Current tax assets	717	2,225
Current inventories	60,417	46,206
Prepayments	22,671	11,586
Other current assets	11,294	9,928
Total current assets	465,543	765,691
Non-current assets		
Non-current financial assets at fair value through other comprehensive income	137,581	0
Non-current financial assets at cost	0	87,000
Property, plant and equipment	424,892	363,827
Intangible assets	12,993	1,957
Deferred tax assets	69,438	56,696
Other non-current assets	8,268	37,628
Total non-current assets	653,172	547,108
Total assets	1,118,715	1,312,799
Current liabilities		
Current contract liabilities	44,199	0
Accounts payable	39,887	9,567
Other payables	95,610	114,951
Other payables to related parties	19	321
Other current liabilities	336	2,941
Total current liabilities	180,051	127,780
Non-current liabilities		
Deferred tax liabilities	1,765	0
Other non-current liabilities	29,884	41,153
Total non-current liabilities	31,649	41,153
Total liabilities	211,700	168,933
Share capital		
Ordinary share	1,099,545	1,121,180
Advance receipts for share capital	0	604
Total share capital	1,099,545	1,121,784
Capital surplus		
Capital surplus, additional paid-in capital	261,501	266,494
Capital surplus, treasury share transactions	0	2,812
Capital surplus, employee share options	39,285	29,856
Total capital surplus	300,786	299,162
Retained earnings		
Unappropriated retained earnings (accumulated deficit)	-519,697	-189,469
Total retained earnings	-519,697	-189,469
Other equity interest		
Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income	26,381	0
Total other equity interest	26,381	0
Treasury shares	0	-87,611
Total equity	907,015	1,143,866
Total liabilities and equity	1,118,715	1,312,799
Equivalent issue shares of advance receipts for ordinary share	0	36,500
Number of shares in entity held by entity and by its subsidiaries	0	2,200,000

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2018/4th	2017/4th
Income Statement		
Total operating revenue	211,424	318,637
Total operating costs	197,317	178,828
Gross profit (loss) from operations	14,107	139,809
Gross profit (loss) from operations	14,107	139,809
Operating expenses		
Selling expenses	21,442	24,780
Administrative expenses	37,430	41,034
Research and development expenses	276,088	195,470
Impairment loss (impairment gain and reversal of impairment loss) determined in accordance with IFRS 9	1,669	0
Total operating expenses	336,629	261,284
Net operating income (loss)	-322,522	-121,475
Non-operating income and expenses		
Total other income	26,908	24,818
Other gains and losses, net	10,119	-109,058
Finance costs, net	296	0
Total non-operating income and expenses	36,731	-84,240
Profit (loss) from continuing operations before tax	-285,791	-205,715
Total tax expense (income)	-11,361	-17,345
Profit (loss) from continuing operations	-274,430	-188,370
Profit (loss)	-274,430	-188,370
Other comprehensive income		
Components of other comprehensive income that will not be reclassified to profit or loss		
Gains (losses) on remeasurements of defined benefit plans	2,153	-1,324
Unrealised gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	-2,409	0
Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	384	-225
Total other comprehensive income	-640	-1,099
Total comprehensive income	-275,070	-189,469
Basic earnings per share		
Total basic earnings per share	-2.50	-1.71

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2018/4th	2017/4th
Statements of Cash Flows		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	-285,791	-205,715
Profit (loss) before tax	-285,791	-205,715
Depreciation expense	77,876	62,448
Amortization expense	2,074	1,026
Expected credit loss (gain) / Provision (reversal of provision) for bad debt expense	1,669	515
Interest expense	296	0
Interest income	-4,898	-5,453
Share-based payments	9,429	15,174
Loss (gain) on disposal of property, plan and equipment	8	-99
Impairment loss on non-financial assets	6,331	2,792
Total adjustments to reconcile profit (loss)	92,785	76,403
Decrease (increase) in contract assets	-5,501	0
Decrease (increase) in accounts receivable	15,100	-44,491
Decrease (increase) in accounts receivable due from related parties	1,240	22,939
Decrease (increase) in other receivable	-8,725	1,660
Decrease (increase) in inventories	-20,542	1,397
Decrease (increase) in prepayments	-11,085	8,106
Adjustments for decrease (increase) in other current assets	-474	-101
Total changes in operating assets	-29,987	-10,490
Increase (decrease) in contract liabilities	42,316	0
Increase (decrease) in accounts payable	30,320	-12,502
Increase (decrease) in other payable	-30,341	71,986
Increase (decrease) in other payable to related parties	-302	315
Adjustments for increase (decrease) in other current liabilities	-722	34,833
Increase (decrease) in net defined benefit liability	-55	-63
Total changes in operating liabilities	41,216	94,569
Total changes in operating assets and liabilities	11,229	84,079
Total adjustments	104,014	160,482
Cash inflow (outflow) generated from operations	-181,777	-45,233
Income taxes refund (paid)	1,508	-317
Net cash flows from (used in) operating activities	-180,269	-45,550
Cash flows from (used in) investing activities		
Acquisition of financial assets at fair value through other comprehensive income	-24,200	0
Acquisition of financial assets at amortised cost	-110,200	0
Proceeds from disposal of financial assets at amortised cost	305,187	0
Acquisition of investments in debt instrument without active market	0	-190,487
Proceeds from disposal of investments in debt instrument without active market	0	392,300
Acquisition of financial assets at cost	0	-67,000
Acquisition of property, plant and equipment	-60,839	-58,847
Proceeds from disposal of property, plant and equipment	124	114
Increase in refundable deposits	-187	-419
Acquisition of intangible assets	-2,330	-344
Increase in other financial assets	-13,493	-9,108
Decrease in other financial assets	12,601	47,683
Increase in prepayments for business facilities	-57,640	-32,659
Increase in other prepayments	-184	-10,780
Interest received	5,114	5,369
Net cash flows from (used in) investing activities	53,953	75,822
Cash flows from (used in) financing activities		
Exercise of employee share options	0	2,018
Net cash flows from (used in) financing activities	0	2,018
Net increase (decrease) in cash and cash equivalents	-126,316	32,290
Cash and cash equivalents at beginning of period	342,061	309,771
Cash and cash equivalents at end of period	215,745	342,061
Cash and cash equivalents reported in the statement of financial position	215,745	342,061

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

2018/12/31 Statement of Stockholders' Equity

Unit: NT\$ thousand

Accounting Title	Ordinary share	Advance receipts for share capital	Total share capital	Capital surplus	Unappropriated retained earnings (accumulated deficit)	Total retained earnings	Unrealised gains (losses) on financial assets measured at fair value through other comprehensive income	Total other equity interest	Treasury shares	Total equity
Equity at beginning of period	1,121,180	604	1,121,784	299,162	-189,469	-189,469	0	0	-87,611	1,143,866
Effects of retrospective application and retrospective restatement	0	0	0	0	0	0	28,790	28,790	0	28,790
Equity at beginning of period after adjustments	1,121,180	604	1,121,784	299,162	-189,469	-189,469	28,790	28,790	-87,611	1,172,656
Profit (loss)	0	0	0	0	-274,430	-274,430	0	0	0	-274,430
Other comprehensive income	0	0	0	0	1,769	1,769	-2,409	-2,409	0	-640
Total comprehensive income	0	0	0	0	-272,661	-272,661	-2,409	-2,409	0	-275,070
Retirement of treasury share	-22,000	0	-22,000	-8,044	-57,567	-57,567	0	0	87,611	0
Share-based payments	365	-604	-239	9,668	0	0	0	0	0	9,429
Total increase (decrease) in equity	-21,635	-604	-22,239	1,624	-330,228	-330,228	-2,409	-2,409	87,611	-265,641
Equity at end of period	1,099,545	0	1,099,545	300,786	-519,697	-519,697	26,381	26,381	0	907,015

2017/12/31 Statement of Stockholders' Equity

Unit: NT\$ thousand

Accounting Title	Ordinary share	Advance receipts for share capital	Total share capital	Capital surplus	Unappropriated retained earnings (accumulated deficit)	Total retained earnings	Unrealised gains (losses) on financial assets measured at fair value through other comprehensive income	Total other equity interest	Treasury shares	Total equity
Equity at beginning of period	1,120,005	807	1,120,812	639,611	-356,669	-356,669	0	0	-87,611	1,316,143
Equity at beginning of period after adjustments	1,120,005	807	1,120,812	639,611	-356,669	-356,669	0	0	-87,611	1,316,143
Capital surplus used to offset accumulated deficits	0	0	0	-356,669	356,669	356,669	0	0	0	0
Profit (loss)	0	0	0	0	-188,370	-188,370	0	0	0	-188,370
Other comprehensive income	0	0	0	0	-1,099	-1,099	0	0	0	-1,099
Total comprehensive income	0	0	0	0	-189,469	-189,469	0	0	0	-189,469
Share-based payments	1,175	-203	972	16,220	0	0	0	0	0	17,192
Total increase (decrease) in equity	1,175	-203	972	-340,449	167,200	167,200	0	0	0	-172,277
Equity at end of period	1,121,180	604	1,121,784	299,162	-189,469	-189,469	0	0	-87,611	1,143,866